Xaira Therapeutics

Visit Website

AI drug discovery powerhouse launched in April 2024 with over $1B in committed capital, incubated by ARCH Venture Partners and Foresite Labs, applying foundation-model AI and large-scale experimental data to drug R&D.

Headquarters

South San Francisco, USA

Year Founded

2024

Founders

Marc Tessier-Lavigne (CEO), with UW Baker Lab science

Country

United States

Financial Information

Funding Stage

Series A (record launch)

Recent Funding

$1B

Funding By

ARCH Venture Partners, Foresite Labs

Core Technology

Foundation-model AI + high-throughput experimental data

Product Type

Drug

Pipeline Stage (Very Important)

Discovery

Regulatory Status

IND Filed: No
FDA/EMA Status: N/A
Clinical Trial Registration: N/A
Patents / IP Status: Building IP portfolio

Partnerships

Pharma Collaborations

In development

Academic / Hospital Tie-ups

Stanford University, University of Washington

CRO/CDMO Partnerships

None disclosed

Market & Differentiation

Largest-ever biotech launch funding + Nobel-winning protein design science